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Abstract
Background: Alpha1-antitrypsin (AAT) deficiency is characterized by low blood levels of alpha1-proteinase inhibitor
(alpha1-PI) and may lead to emphysema. Alpha1-PI protects pulmonary tissue from damage caused by the action
of proteolytic enzymes. Augmentation therapy with Prolastin® (Alpha1-Proteinase Inhibitor [Human]) to increase the
levels of alpha1-PI has been used to treat individuals with AAT deficiency for over 20 years. Modifications to the
Prolastin manufacturing process, incorporating additional purification and pathogen-reduction steps, have led to
the development of an alpha1-PI product, designated Prolastin®-C (Alpha1-Proteinase inhibitor [Human]). The
pharmacokinetic comparability of Prolastin-C to Prolastin was assessed in subjects with AAT deficiency.
Methods: In total, 24 subjects were randomized to receive 60 mg/kg of functionally active Prolastin-C or Prolastin
by weekly intravenous infusion for 8 weeks before crossover to the alternate treatment for another 8 weeks.
Pharmacokinetic plasma samples were drawn over 7 days following last dose in the first treatment period and over
10 days following the last dose in the second period. The primary end point for pharmacokinetic comparability
was area under the plasma concentration versus time curve over 7 days post dose (AUC0-7 days) of alpha1-PI
determined by potency (functional activity) assay. The crossover phase was followed by an 8-week open-label
treatment phase with Prolastin-C only.
Results: Mean AUC0-7 days was 155.9 versus 152.4 mg*h/mL for Prolastin-C and Prolastin, respectively. The
geometric least squares mean ratio of AUC0-7 days for Prolastin-C versus Prolastin had a point estimate of 1.03 and a
90% confidence interval of 0.97-1.09, demonstrating pharmacokinetic equivalence between the 2 products. Adverse
events were similar for both treatments and occurred at a rate of 0.117 and 0.078 per infusion for Prolastin-C
(double-blind treatment phase only) and Prolastin, respectively (p = 0.744). There were no treatment-emergent viral
infections in any subject for human immunodeficiency virus, hepatitis B or C, or parvovirus B19 during the course
of the study.
Conclusion: Prolastin-C demonstrated pharmacokinetic equivalence and a comparable safety profile to Prolastin.
Trial Registration: ClinicalTrials.gov Identifier: NCT00295061.
Background
Alpha1-antitrypsin (AAT) deficiency is an inherited
autosomal disorder characterized by low blood levels of
alpha1-proteinase inhibitor (alpha1-PI) and is one of the
most common yet under recognized single-locus genetic
diseases [1]. The disorder may lead to progressive severe
emphysema that can manifest as early as the fourth dec-
ade of life [2,3].
Alpha1-PI protects the lung from damage by proteoly-
tic enzymes (particularly neutrophil elastase) due to its
action as an inhibitor of serine proteinases. Neutrophil
elastase is released in the lung in response to inflamma-
tion and infection and can destroy the elastin in healthy
pulmonary tissue. Neutrophil elastase is normally
* Correspondence: james.stocks@uthct.edu
1Department of Medicine, University of Texas Health Science Center at Tyler,
11937 US Hwy 271, Tyler, TX 75708-3154, USA
Full list of author information is available at the end of the article
Stocks et al. BMC Clinical Pharmacology 2010, 10:13
http://www.biomedcentral.com/1472-6904/10/13
© 2010 Stocks et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.inactivated by alpha1-PI and the lung is protected, but in
individuals with a deficiency of alpha1-PI, neutrophil
elastase may cause irreversible destruction of pulmonary
structures resulting in the development of emphysema.
The most specific approach to treating AAT defi-
ciency is augmentation of low serum AAT levels with
purified alpha1-PI through intravenous infusion in order
to maintain plasma levels above 11 μM. Plasma alpha1-
PI concentrations above a threshold of 11 μMa r ec o n -
sidered to be sufficiently protective against lung disease
progression in individuals with AAT deficiency [4]. Pro-
lastin® (Alpha1-Proteinase Inhibitor [Human], Talecris
Biotherapeutics, Research Triangle Park, NC, USA) is a
plasma-derived protein that has been administered as
augmentation therapy to individuals with AAT defi-
ciency for more than 20 years. In 2003, two other pre-
parations of alpha1-PI, Aralast (Baxter, Westlake Village,
California, USA) and Zemaira (CSL Behring, Kankakee,
Illinois, USA) were introduced in the United States.
Non-randomized observational studies have demon-
strated a slower decline in lung function for subjects
receiving Prolastin compared with those not receiving
the augmentation therapy [5-7]. In addition, Prolastin
has a proven tolerability [8-10] and pathogen safety
record [11]. Scientific advances since the introduction of
Prolastin have made it possible to incorporate modifica-
tions to the manufacturing process [12-14]. These
include an additional cation exchange chromatography
polishing step (to provide further purification), and
improved ultrafiltration and diafiltration. Two new dedi-
cated virus-reduction steps, solvent/detergent treatment
and 15 nm nanofiltration, replace the pasteurization
step in the Prolastin process.
These modifications to the Prolastin manufacturing
process have led to the development of an alpha1-PI
product, designated Prolastin®-C (Alpha1-Proteinase
Inhibitor [Human]), with increased purity, a higher con-
centration of active alpha1-PI, and, as demonstrated in
laboratory studies, a higher margin of safety from the
risk of transmission of infectious pathogens.
The aim of this study was to investigate the pharma-
cokinetic characteristics of Prolastin-C in individuals
with AAT deficiency and to compare these characteris-
tics with those of Prolastin in support of licensing Pro-
lastin-C. We report here the results of a multicenter,
randomized, double-blind, crossover trial. We also
assessed the tolerability and safety profile of Prolastin-C.
Methods
Subjects
Men and women aged ≥ 18 years were eligible for inclu-
sion in the study if they had a documented diagnosis of
congenital AAT deficiency with genotype PiZZ, PiZ
Null, Pi Null Null, or other predefined “at-risk” alleles.
Subjects must have received augmentation therapy with
Prolastin for at least 1 month prior to study start. In
addition, all subjects must have had documented alpha1-
PI serum levels of < 11 μM prior to receiving any aug-
mentation therapy and a forced expiratory volume in 1
second of 20% to 80% predicted value within the pre-
vious 6 months. All subjects provided written informed
consent prior to study participation. Subjects were
excluded from the study if they had a diagnosis of liver
cirrhosis, any severe concomitant disease, history of ana-
phylaxis to plasma-derived alpha1-PI or other blood pro-
duct, known immunoglobulin A (IgA) deficiency, or
exacerbations of their pulmonary disease within 1
month of study entry. Use of systemic steroids prior to
2 weeks of receipt of study medication (excluding
inhaled steroids used on a routine or as-needed basis)
was also not permitted. The study was approved by the
following local ethics review committees: University of
Florida Health Science Center Institutional Review
Board, National Jewish Medical Center and Research
Center Institutional Review Board, University of Texas
Health Center at Tyler Institutional Review Board,
Western Institutional Review Board, and the Medical
University of South Carolina Institutional Review Board
for Human Research. The study was conducted in
accordance with the Declaration of Helsinki and Good
Clinical Practice guidelines.
Study design
This multicenter, randomized, double-blind study con-
sisted of a 16-week crossover phase to evaluate the
pharmacokinetic comparability between Prolastin-C and
Prolastin (an initial 8-week treatment period and a sec-
ond 8-week period based on the alternate treatment),
followed by an 8-week open-label treatment phase with
Prolastin-C only (Figure 1). Subjects were randomized
in a 1:1 ratio. Each site was provided with randomiza-
tion envelopes in numerical order and with the rando-
mization number visible on the outside. Randomization
envelopes were sent to the pharmacist with study medi-
cation. The 6-digit randomization numbers were
assigned to subjects in ascending order at the baseline
visit, when the subject’s eligibility had been confirmed.
Subjects received a weekly intravenous infusion of either
60 mg/kg body weight of functionally active Prolastin-C
or 60 mg/kg functionally active Prolastin determined by
potency assay during the first 8-week treatment period.
Since Prolastin-C is reconstituted in half the volume of
diluent compared with Prolastin, treatment was admi-
nistered in 2 infusion bags of equal volume for each
product: in the case of Prolastin-C, the first bag con-
tained normal saline and the second Prolastin-C. For
Prolastin total volume was split equally into 2 infusion
bags. This was done in order to maintain the blinding.
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blinding methods would require dilution of the product
to achieve volumes identical to Prolastin in each bag.
The method used enabled assessment of the safety and
tolerability of Prolastin-C as it would be used in clinical
practice (ie, in a “real world” situation). Each infusion
bag was administered over approximately 15 minutes
such that the total infusion time for each treatment was
30 minutes.
Blood sampling
In the first treatment period, a pre-infusion blood sam-
ple was drawn for pharmacokinetic analysis prior to the
last dose of study medication (Week 8). Following this
last dose, a total of 10 serial samples were drawn over 7
days at nominal time 0.25 h, 0.5 h, 0.75 h, 2.5 h, 4.5 h,
8.5 h, 24.5 h, 48.5 h, 120.5 h, and 168.5 h after complet-
ing infusion of the first infusion bag (Figure 1). Subjects
were then crossed over to the alternate treatment. In
the second treatment period, a pre-infusion blood sam-
ple was again taken prior to the last dose of study medi-
cation (Week 16), followed by 11 serial blood samples
over 10 days after the last dose at nominal time 0.25 h,
0.5 h, 0.75 h, 2.5 h, 4.5 h, 8.5 h, 24.5 h, 48.5 h, 120.5 h,
1 6 8 . 5h ,a n d2 4 0 . 5ha f t e rc o m p l e t i n gi n f u s i o no ft h e
first infusion bag and before the start of the 8-week
open-label treatment phase (Figure 1). In addition,
blood samples were drawn for the determination of
trough levels of alpha1-PI before the start of the infusion
at Weeks 6, 7, and 8, and at Weeks 14, 15, and 16. Dur-
ing the open-label treatment phase (Weeks 17-24), all
subjects received 60 mg/kg body weight Prolastin-C
exclusively for 8 weeks.
Blood was collected into two tubes containing 4.5 ml
of sodium citrate. The contents of the tubes were mixed
gently and centrifuged at 2500 × g for 15 minutes. The
plasma was transferred equally into two 3-ml cryovials
using a disposable pipette, without disturbing the buffy
coat (white blood cells) or the red blood cells. Each ali-
quot was required to contain an equal amount of
sodium citrate solution and at least 1 ml of plasma. The
samples were frozen immediately. The measurement of
the alpha1-PI concentration in plasma was adjusted to
account for the presence of sodium citrate.
Pharmacokinetic parameters
For pharmacokinetic evaluation, plasma samples were
analyzed for concentrations of alpha1-PI using (a) a
Figure 1 Study design.
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active concentration of protein capable of inhibiting
neutrophil elastase (via a colorimetric method [15]), and
(b) a content (antigenic) assay based on immunoprecipi-
tation of soluble alpha1-PI antigen, using a correspond-
ing alpha1-PI antiserum to measure both functionally
active and inactive forms of the protein (by immunone-
phelometry [Behring Nephelometer BNII]). Both vali-
dated assays were applied to the analysis of each plasma
sample. The concentration data are reported in the unit
of mg/mL, and also in the unit of μM from the content
assay in conformance with historical data. For the
potency assay, the conversion factor is 1 mg/mL alpha1-
PI equivalent to 19.2 μM. For the content assay, 1 mg/
mL alpha1-PI is equivalent to 22.6 μM. The lower limit
of quantification for alpha1-PI in plasma using the
potency assay was 0.007 mg/mL and 0.07 mg/mL using
the content assay.
O n l yt h er e s u l t so ft h ep o t e n c ya s s a yw e r eu s e df o r
primary statistical analyses to determine pharmacoki-
netic comparability between the 2 treatments. The pri-
mary pharmacokinetic parameter used for treatment
comparison was the area under the plasma alpha1-PI
concentration versus time curve over 7 days’ post-infu-
sion (AUC0-7 days) at steady state (ie, after the last dose
administered in each treatment period). Using the
potency assay results for the primary pharmacokinetic
parameter eliminates the inherent bias in plasma con-
centrations of total antigenic alpha1-PI between the 2
products with different antigenic content but adminis-
tered at the same dose based on potency. Since the con-
tent assay has been used historically to report serum
levels of alpha1-PI, especially trough levels, it was also
performed to provide supportive data for historical
comparison.
Other pharmacokinetic parameters determined for
alpha1-PI included first observed peak plasma alpha1-PI
concentration following drug infusion (Cmax), time to
reach observed Cmax (tmax), terminal half-life (t1/2),
observed plasma alpha1-PI trough concentration prior to
the start of infusions (Ctrough), and average trough con-
centration of alpha1-PI at steady state (mean Ctrough).
The pharmacokinetic parameters of alpha1-PI at steady
state were calculated at the end of the first and second
8-week double-blind treatment periods using noncom-
partmental pharmacokineticm e t h o d sw i t hW i n N o n L i n
Professional Software, version 4.1 (Pharsight Corpora-
tion, Mountain View, California, USA).
Safety profile
Safety data included frequency and nature of adverse
events (AEs), exacerbations of pulmonary disease, vital
signs, and laboratory data. Alpha1-PI antibody testing
was also performed by Prolastin-C antibody screening
enzyme-linked immunosorbent assay with a detection
limit of 250 ng/mL. Subjects also underwent testing for
human immunodeficiency virus (HIV), hepatitis B virus
(HBV), hepatitis C virus (HCV), and parvovirus B19
using viral nucleic acid testing by polymerase chain
reaction (PCR) at baseline and Weeks 9 and 17, and
nucleic acid testing by PCR and viral serology testing at
study end (Week 24). If a viral serology test result was
positive at Week 24, or if any PCR result was positive at
any time point during the study, then the sample
retained at baseline was serologically tested.
Statistical methods
The sample size of 20 subjects (10 subjects per treat-
ment sequence) was sufficient to demonstrate compar-
ability with regard to AUC0-7days with 90% power up to
a standard deviation of 0.288 of the difference in the
loge scale (this corresponds to a mean square error in
the ANOVA ≤ 0.041) under the assumption of an
expected mean treatment difference of 0 (or treatment
ratio of 1), a lower equivalence limit of -0.223 (= loge
0.8), an upper equivalence limit of 0.223 (= loge 1.25),
and a one-sided alpha of 0.05 (corresponds to a 90%
confidence interval [CI]).
The study populations for analysis included the intent-
to-treat population, which was defined as all randomized
subjects; the safety population, which included all sub-
jects who received any study medication; and the phar-
macokinetic population, which comprised all subjects
who received study medication and had sufficient
plasma alpha1-PI concentration data to facilitate calcula-
tion of pharmacokinetic parameters.
Descriptive statistics were calculated for baseline vari-
ables and for each pharmacokinetic parameter deter-
mined from alpha1-PI concentration data by both
potency and content assays. In order to compare the
primary pharmacokinetic parameter (AUC0-7 days)
between the 2 products, loge-transformed AUC0-7 days
values were analyzed by analysis of variance, with treat-
ment, treatment sequence, and study period as fixed
effects, and subject (nested within sequence) as a ran-
dom effect. A Wilcoxon Rank test was used to compare
the AE rates between Prolastin-C and Prolastin. All sta-
tistical analyses and summaries were produced using
SAS® version 8.2 (or higher).
Results
Subject disposition and baseline characteristics
A total of 28 subjects were screened, 24 were rando-
mized (12 to each treatment sequence, ie, Prolastin
treatment followed by Prolastin-C treatment, or Prolas-
tin-C treatment followed by Prolastin treatment), and 24
were eligible for pharmacokinetic analysis (Figure 2).
Four subjects were discontinued prior to randomization
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randomized subjects completed both the double-blind
treatment phase and the open-label phase. Subject
demographics and baseline characteristics were similar
between treatment sequences and are shown in Table 1.
A diagnosis of severe AAT deficiency was confirmed by
t h ep r e s e n c eo ft h eP i Z Zg e n o t y p ei n2 3o f2 4s u b j e c t s
and by the genotype PiSZ in 1 subject. All subjects had
received prior therapy with Prolastin.
Pharmacokinetic evaluation
Among the 24 subjects in the pharmacokinetic popula-
tion, 1 subject missed the infusion at Week 8 when Pro-
lastin-C was to be administered and 2 subjects receiving
Prolastin at Week 8 did not have sufficient data points
for determination of AUC0-7 days or other pharmacoki-
netic parameters due to sample hemolysis affecting the
potency assay. Sample hemolysis affected the content
assay of samples from 1 subject following Prolastin
treatment.
Primary end point for pharmacokinetic comparability
T h em e a np l a s m aa l p h a 1-PI concentration versus time
p l o t sa sd e t e r m i n e db yt h ep o t e n c ya s s a ys h o wt h a t
plasma alpha1-PI concentrations versus time curves
derived from the 2 products were almost superimposa-
ble (Figure 3). The mean AUC0-7 days was 155.9 mg*h/
mL for Prolastin-C (n = 23) and 152.4 mg*h/mL for
Prolastin (n = 22) (Table 2). The geometric least squares
mean ratio of AUC0-7 days Prolastin-C versus Prolastin,
had a point estimate and 90% CI of 1.03 and 0.97-1.09,
respectively, for the potency assay results (Table 3). The
90% CI falls within the limit of 0.80-1.25, a criterion for
concluding bioequivalence between treatments based on
U.S. Food and Drug Administration (FDA) guidance
[16].
Other pharmacokinetic parameters
The other pharmacokinetic parameters were similar for
both treatments based on the potency assay (Table 2).
A slightly shorter median tmax was measured for Prolas-
tin-C compared with Prolastin (0.673 hour versus 0.820
hour, respectively). The 90% CI interval for the geo-
metric least squares mean ratio of Cmax for Prolastin-C
versus Prolastin based on the potency assay (0.92-1.04)
was also within the limit of 0.80-1.25.
Pharmacokinetic parameters by content assay
Using the content assay, the mean AUC0-7 days was
190.1 mg*h/mL for Prolastin-C (n = 23) and 194.8
m g * h / m Lf o rP r o l a s t i n( n=23), respectively. As an
exploratory comparison, the 90% CI values for the geo-
metric least squares mean ratio of AUC0-7 days,P r o l a s -
tin-C versus Prolastin, also fell within the limit of 0.80-
1.25 (Table 3). Mean plasma concentration versus time
curves were similar between treatments with the excep-
tion of the distribution phase, where Prolastin elicited a
higher Cmax compared with Prolastin-C (Figure 4).
There were no major differences in other pharmacoki-
netic parameters for alpha1-PI measured between treat-
ments based on the content assay except that median
tmax was slightly shorter for Prolastin-C (0.703 hour)
than for Prolastin (0.955 hour). For comparison with
historical data, Ctrough based on the content assay was
evaluated (Table 4). All subjects, following each
Figure 2 Subject disposition.
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above the historical target level of 11 μM.
Safety results
Treatment exposure
A total of 188 weekly infusions of Prolastin-C and 192
weekly infusions of Prolastin were administered in the
double-blind crossover phase. A further 192 weekly
infusions of Prolastin-C were administered in the open-
label treatment phase, resulting in a total of 380 weekly
infusions of Prolastin-C throughout the whole study.
Adverse events
AEs occurring in the double-blind crossover and open-
label phases are summarized in Table 5. During the
entire study (double-blind crossover plus open-label
phases), a total of 36 AEs were reported in subjects
receiving Prolastin-C, giving a rate of 0.095 AEs per
infusion. For the crossover phase, the rate of AEs per
infusion was 0.117 in the subjects treated with Prolas-
tin-C and 0.078 during Prolastin treatment (Table 5). A
Wilcoxon Rank test gave a p-value of 0.744, which sug-
gested no significant difference between the 2 treat-
ments for the rates of AEs during the crossover phase.
The most frequently reported AEs (occurring in ≥ 2
subjects) in the crossover phase were upper respiratory
tract infection in subjects treated with Prolastin-C and
headache and arthralgia in those treated with Prolastin.
During the open-label phase, the most frequently occur-
ring AEs in Prolastin-C-treated subjects were urinary
tract infection and rales (Table 5). During Prolastin-C
treatment, 2 AEs (2 episodes of pruritus in a single sub-
ject), representing a rate of 0.005 AEs per infusion, were
considered to be related to study drug; 1 case occurred
in the double-blind crossover phase and 1 in the open-
label phase.
The majority of AEs were considered to be mild to
moderate in severity. Only 2 serious AEs were reported
during the study: a single subject experienced severe
spinal osteoarthritis and severe cervical spinal stenosis
after 8 weeks of double-blind treatment with Prolastin,
which were not considered to be related to study medi-
cation. No deaths or premature discontinuations due to
AEs were reported in this study. Ten pulmonary exacer-
bations were observed in 8 patients during the study: 8
in the double-blind crossover phase (4 on Prolastin and
4 on Prolastin-C) and 2 in the open-label phase. Eight
Table 1 Subject Demographics by Treatment Sequence (ITT Population)
Prolastin/Prolastin-C (n = 12) Prolastin-C/Prolastin (n = 12) All Subjects (n = 24)
Mean age, y (SD) 57.0 (9.33) 58.4 (6.86) 57.7 (8.04)
Mean body weight, kg (SD) 81.4 (15.37) 89.7 (19.49) 85.5 (17.67)
Male gender, n (%) 4 (33.3) 6 (50.0) 10 (41.7)
Female gender, n (%) 8 (66.7) 6 (50.0) 14 (58.3)
Time since AAT deficiency diagnosis, y (SD) 8.69 (6.96) 9.10 (6.02) 8.89 (6.37)
Mean pre-augmentation alpha1-PI plasma level, μM (SD) 5.29 (1.90) 4.92 (2.01) 5.11 (1.92)
Mean baseline alpha1-PI serum level, μM (SD)* 17.7 (3.26) 19.8 (4.38) 18.7 (3.91)
Mean FEV1 predicted, % (SD) 43.8 (13.2) 41.8 (13.8) 42.8 (13.3)
Deficiency genotype, n (%)
PiZZ 12 (100) 11 (91.7) 23 (95.8)
PiSZ 0 1 (8.3) 1 (4.2)
Prior Prolastin therapy, n (%) 12 (100) 12 (100) 24 (100)
Medical history, n (%)
†
Obstructive pulmonary diseases
‡
COPD 8 (66.7) 7 (58.3) 15 (62.5)
Emphysema 6 (50.0) 7 (58.3) 13 (54.2)
Bronchiectasis 3 (25.0) 2 (16.7) 5 (20.8)
Asthma 3 (25.0) 3 (25.0) 6 (25.0)
Other conditions
Headache 3 (25.0) 4 (33.3) 7 (29.2)
Pneumonia 2 (16.7) 3 (25.0) 5 (20.8)
Depression 2 (16.7) 3 (25.0) 5 (20.8)
Hypertension 2 (16.7) 3 (25.0) 5 (20.8)
COPD = chronic obstructive pulmonary disease; FEV1 = forced expiratory volume in 1 second; ITT = intent to treat. *By content (antigenic) assay (n = 22).
†Occurring in ≥ 5 subjects.
‡Pulmonary diagnosis reported in study documentation.
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Prolastin-C [3 in the crossover phase and 2 in the open-
label phase] and 3 on Prolastin), and 2 were considered
mild (1 each for Prolastin and Prolastin-C). No exacer-
bation of pulmonary disease was severe or considered to
be a serious AE. All were resolved within approximately
2 weeks with drug therapy.
Viral testing
There were no treatment-emergent viral infections in
any subject for HIV, HBV, HCV, or parvovirus B19 dur-
ing the course of the study as measured by nucleic acid
testing by PCR or viral serology. Evidence of a prior par-
vovirus B19 infection was observed in 18/24 subjects
(75%). These subjects tested negative for parvovirus B19
IgM antibodies and positive for parvovirus B19 IgG anti-
bodies at baseline and Week 24, and negative for parvo-
virus DNA throughout the study. In addition, these
Figure 3 Mean plasma alpha1-PI concentration versus time curves following treatment with Prolastin-C or Prolastin: potency
[functional activity] assay results.
Table 2 Summary of Pharmacokinetic Parameters of
Plasma Alpha1-PI Determined by Potency [Functional
Activity] Assay
Prolastin-C 60
mg/kg
Prolastin 60 mg/
kg
Mean AUC0-7 days, mg*h/mL
(% CV)
155.9 (17) 152.4 (16)
n=2 3 n=2 2
Mean Cmax, mg/mL (% CV) 1.797 (10) 1.848 (15)
n=2 2 n=2 3
Median adjusted tmax,h r
(range)
0.673 (0.23-2.59) 0.820 (0.25-2.90)
n=2 2 n=2 3
Mean t½, hr (% CV) 146.3 (16) 139.3 (18)
n=2 2 n=2 2
CV = coefficient of variation.
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infection.
Other safety data
There were no clinically relevant differences between
Prolastin-C and Prolastin with respect to laboratory
assessments (hematology, clinical chemistry, and urina-
lysis parameters) or vital signs throughout the study. All
study samples were negative for antibodies to alpha1-PI.
Discussion
This study describes the first human administration of
Prolastin-C, a new concentrated form of alpha1-PI
prepared from human plasma for administration as
augmentation therapy to individuals with AAT defi-
ciency. Since it has increased purity and a higher con-
centration of alpha1-PI in comparison with Prolastin,
Prolastin-C has the potential to be administered with a
shorter infusion time and, therefore, may offer improved
convenience for patients receiving weekly doses of
alpha1-PI.
The study was designed to evaluate the pharmacoki-
netic profile of Prolastin-C and to assess the pharmaco-
kinetic comparability of Prolastin-C to Prolastin in
subjects with AAT deficiency. Bioequivalence was
demonstrated between the 2 alpha1-PI preparations,
both administered at a dose of 60 mg/kg body weight
Table 3 Ratio of Point Estimates and 90% CIs for AUC0-7 days for Prolastin-C versus Prolastin
Geometric least squares mean ratio: Prolastin-C versus Prolastin
Potency assay Content assay
Point estimate 90% CI Point estimate 90% CI
AUC0-7 days, mg*h/mL 1.03 0.97-1.09 0.98 0.95-1.02
Figure 4 Mean plasma alpha1-PI concentration versus time curves following treatment with Prolastin-C or Prolastin: content
[antigenic] assay results.
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metric least squares mean ratio for AUC0-7 days by
potency assay, the primary end point, Prolastin-C versus
Prolastin, was 0.97-1.09, which was within the limit that
defines bioequivalence between 2 products according to
FDA guidance, namely 0.80-1.25 [16]. This demonstra-
tion of bioequivalence between Prolastin and Prolastin-
C provides clinicians with the confidence that Prolastin-
C will have a comparable pharmacokinetic profile.
Patients prescribed Prolastin-C will maintain similar
overall plasma exposure to alpha1-PI as they had with
Prolastin. In addition, Prolastin-C has improved purity
and a higher concentration of alpha1-PI.
Augmentation therapy for AAT-deficient patients has
been through intravenous administration of alpha1-PI
with the dose amount based on the functionally active
alpha1-PI in the drug product, measured by the func-
tional activity assay. Historically, augmentation therapy
has been evaluated by measuring the rise in serum con-
centrations of alpha1-PI using an antigenic content assay
after administration of an alpha1-PI product. The anti-
genic content assay measures both functionally active
and non-active forms of alpha1-PI. The functionally
inactive forms may include oxidized, oligomerized, and
polymerized forms of the alpha1-PI protein.
It has previously been shown that some alpha1-PI pre-
parations have a higher antigenic content than function-
ally active content, which results in differences in the
specific activity of alpha1-PI products. When dose is
determined based on the amount of functionally active
alpha1-PI, the product with a lower specific activity
would be administered at a higher amount of total or
antigenic content of alpha1-PI, potentially resulting in
higher concentrations of the alpha1-PI antigenic content
in plasma. Therefore, using the content assay to assess
pharmacokinetic comparability between 2 products with
different specific activities (eg, Prolastin with ≥ 0.35 mg
functional alpha1-PI per milligram of total protein ver-
sus Prolastin-C with ≥ 0.8 mg per milligram of total
protein) introduces an inherent bias in the comparison.
In order to eliminate this bias, the potency assay was
employed to measure concentrations of functionally
active alpha1-PI in the systemic circulation and to assess
pharmacokinetic comparability between the 2 products
(Prolastin-C and Prolastin), administered at the same
dose amount of the functionally active alpha1-PI. Since
the content assay has been used historically to measure
systemic exposure to alpha1-PI for its protective effect
to maintain plasma levels above a threshold of 11 μM
[4], the results from the content assay, as well as those
from the potency assay, were used in the graphical
representation of plasma alpha1-PI concentration versus
Table 4 Summary of Steady-State Trough Concentrations
of Plasma Alpha1-PI Determined by Content [Antigenic]
Assay
Prolastin-C 60
mg/kg
Prolastin 60
mg/kg
Mean Ctrough, μM (% CV) 16.9 (14) 16.7 (16)
n=2 3 n=2 4
Subjects with mean Ctrough ≥
11 μM
23/23 (100%) 24/24 (100%)
One subject missed a Prolastin-C infusion at Week 8. Therefore, only 23 data
sets were available for determination of Ctrough following Prolastin-C
treatment.
Table 5 Summary of AEs
Double-blind Crossover Phase Open-label Phase
Prolastin-C (n = 24)
8 Weeks
Prolastin (n = 24)
8 Weeks
Prolastin-C (n = 24)
8 Weeks
AEs by subject
Any AE, n (%) 11 (45.8) 9 (37.5) 11 (45.8)
AEs by total number and rate per infusion
Total number of AEs (rate per infusion) 22 (0.117) 15 (0.078) 14 (0.073)
Total number of AEs occurring in ≥ 2 subjects (rate per infusion)
Upper respiratory tract infection 2 (0.011) 1 (0.005) 1 (0.005)
Urinary tract infection 1 (0.005) 0 2 (0.010)
Headache 1 (0.005) 2 (0.010) 0
Rales 0 0 2 (0.010)
Arthralgia 0 2 (0.010) 0
AEs leading to withdrawal 0 0 0
Total number of SAEs (rate per infusion) 0 2 (0.010) 0
Deaths 0 0 0
Total number of weekly infusions: Prolastin-C, 380 (double-blind plus open-label phases); 188 (double-blind phase only); 192 (open-label phase only). Prolastin,
192 (double-blind phase only).
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(Figures 3 and 4). It should be noted that it is not possi-
ble, or appropriate, to compare results between 2 assay
methods that measure different entities (ie, one for
functionally active protein and the other for functionally
active and inactive proteins), as different reference stan-
dards are used to establish the calibration curves.
While the primary end point for pharmacokinetic
comparability of this study was based on data from the
potency assay, results derived from the content assay
also demonstrated pharmacokinetic comparability
between the 2 alpha1-PI preparations, based on the 90%
CI (0.95-1.02) of the geometric least squares mean ratio
of AUC0-7 days, Prolastin-C versus Prolastin.
Mean values of other key pharmacokinetic parameters
(including Cmax,t max,t 1/2,a n dm e a nC trough) derived
from the potency and content assays were also compar-
able between Prolastin-C and Prolastin. Analysis of the
data for Cmax using the potency assay showed that the
90% CI values of the geometric least squares mean
ratios for Prolastin-C versus Prolastin (0.92-1.04) were
also within the limit defined by the FDA guidance for
bioequivalence. This result is encouraging, even though
the study was not designed to compare Cmax between
products, because Cmax would vary with the rate of infu-
sion, which is the case of this study (ie, 4 mg/kg/min for
Prolastin-C and 2 mg/kg/min for Prolastin). Slightly
higher Cmax of alpha1-PI concentrations were measured
following Prolastin treatment compared with Prolastin-
C treatment using the content assay. Prolastin was
administered at a greater total protein “antigenic con-
tent” than Prolastin-C, which could potentially result in
higher plasma concentrations of alpha1-PI antigenic
content especially during the early phase shortly after
infusion. The higher antigenic content of Prolastin
results from its lower specific activity versus that for
Prolastin-C.
A slightly shorter tmax (by approximately 0.15-0.25
hour) was observed for Prolastin-C compared with Pro-
lastin, using both the potency and content assays. This
may be explained by the shorter infusion time for Pro-
lastin-C (over 15 minutes) compared with Prolastin
(over 30 minutes) because Prolastin-C was reconstituted
in half the diluent of Prolastin, and therefore the infu-
sion time for Prolastin-C was reduced by 50%. This
slight difference in tmax between the 2 treatments,
mainly introduced by trial design, would not be clini-
cally meaningful, considering how Prolastin-C will be
used in the clinic. There were no substantial differences
between Prolastin-C and Prolastin in mean t1/2 estimates
for alpha1-PI based on the results of the potency assay
(146.3 and 139.3 hours, respectively). The mean t1/2
values obtained using the content assay were also com-
parable between Prolastin-C and Prolastin. These values
support the once-weekly dosing schedule for each
treatment.
In this study, mean Ctrough concentrations for plasma
alpha1-PI derived from the content assay were at levels
that maintained a protective concentration of alpha1-PI.
Furthermore, all subjects receiving either of the 2 treat-
ments achieved mean Ctrough levels of alpha1-PI above
the historical target threshold of 11 μM.
Both Prolastin-C and Prolastin were well tolerated,
and there was no statistically significant difference
between the rates of AEs per infusion between the 2
treatments. The safety profiles of Prolastin-C and Pro-
lastin in this study were similar to those previously
described for weekly Prolastin infusions. The observa-
tions with Prolastin-C are consistent with the known
Prolastin risk profile, and no unexpected safety findings
were reported. The results also confirmed the virus
safety of Prolastin-C.
Conclusion
For more than 20 years, Prolastin has been one of the
mainstays of treatment for AAT deficiency. Compared
with the Prolastin manufacturing process, the Prolastin-
C modified process provides greater purity, a higher
concentration of active alpha1-PI, and a high margin of
safety from the risk of transmission of infectious patho-
gens. Given the pharmacokinetic comparability and
similar safety profiles between Prolastin-C and Prolastin
as demonstrated by this study, Prolastin-C is a safe and
effective therapy for individuals with AAT deficiency.
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